Oncolytics Biotech Future Growth
Future criteria checks 2/6
Oncolytics Biotech is forecast to grow earnings and revenue by 57.5% and 63% per annum respectively while EPS is expected to grow by 58.2% per annum.
Key information
57.5%
Earnings growth rate
58.2%
EPS growth rate
Biotechs earnings growth | 37.1% |
Revenue growth rate | 63.0% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 04 Apr 2024 |
Recent future growth updates
Recent updates
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Feb 23Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Jul 07Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Mar 24Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?
Dec 09We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate
Aug 25Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
May 12We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Dec 02We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Aug 05Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth
Apr 15We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Dec 31Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 38 | -20 | -79 | -74 | 4 |
12/31/2025 | 7 | -41 | -66 | -61 | 6 |
12/31/2024 | 1 | -36 | -59 | -43 | 7 |
12/31/2023 | N/A | -28 | -28 | -28 | N/A |
9/30/2023 | N/A | -32 | -28 | -28 | N/A |
6/30/2023 | N/A | -27 | -26 | -26 | N/A |
3/31/2023 | N/A | -24 | -25 | -25 | N/A |
12/31/2022 | N/A | -25 | -23 | -23 | N/A |
9/30/2022 | N/A | -24 | -24 | -24 | N/A |
6/30/2022 | N/A | -24 | -24 | -23 | N/A |
3/31/2022 | N/A | -27 | -23 | -23 | N/A |
12/31/2021 | N/A | -26 | -23 | -22 | N/A |
9/30/2021 | N/A | -28 | -22 | -22 | N/A |
6/30/2021 | N/A | -30 | -24 | -24 | N/A |
3/31/2021 | N/A | -29 | -24 | -24 | N/A |
12/31/2020 | N/A | -23 | -22 | -22 | N/A |
9/30/2020 | N/A | -33 | -24 | -24 | N/A |
6/30/2020 | N/A | -29 | -22 | -22 | N/A |
3/31/2020 | N/A | -28 | -20 | -20 | N/A |
12/31/2019 | N/A | -33 | -20 | -20 | N/A |
9/30/2019 | N/A | -19 | -17 | -17 | N/A |
6/30/2019 | N/A | -18 | -16 | -16 | N/A |
3/31/2019 | N/A | -17 | -11 | -11 | N/A |
12/31/2018 | N/A | -17 | -12 | -12 | N/A |
9/30/2018 | N/A | -17 | -11 | -11 | N/A |
6/30/2018 | N/A | -17 | -11 | -10 | N/A |
3/31/2018 | N/A | -17 | -16 | -16 | N/A |
12/31/2017 | N/A | -16 | -15 | -15 | N/A |
9/30/2017 | N/A | -16 | N/A | -15 | N/A |
6/30/2017 | N/A | -16 | N/A | -15 | N/A |
3/31/2017 | N/A | -15 | N/A | -13 | N/A |
12/31/2016 | N/A | -15 | N/A | -12 | N/A |
9/30/2016 | N/A | -13 | N/A | -13 | N/A |
6/30/2016 | N/A | -13 | N/A | -13 | N/A |
3/31/2016 | N/A | -14 | N/A | -15 | N/A |
12/31/2015 | N/A | -14 | N/A | -15 | N/A |
9/30/2015 | N/A | -14 | N/A | -14 | N/A |
6/30/2015 | N/A | -16 | N/A | -16 | N/A |
3/31/2015 | N/A | -17 | N/A | -16 | N/A |
12/31/2014 | N/A | -19 | N/A | -20 | N/A |
9/30/2014 | N/A | -21 | N/A | -21 | N/A |
6/30/2014 | N/A | -22 | N/A | -23 | N/A |
3/31/2014 | N/A | -22 | N/A | -22 | N/A |
12/31/2013 | N/A | -24 | N/A | -24 | N/A |
9/30/2013 | N/A | -26 | N/A | -27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ONC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ONC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ONC's revenue (63% per year) is forecast to grow faster than the Canadian market (6.6% per year).
High Growth Revenue: ONC's revenue (63% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ONC's Return on Equity is forecast to be high in 3 years time